Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วCalifornia Immunology Research Bond Proposition
California Immunology Research Bond Proposition
0% โอกาส
ใหม่
ใหม่
Nov 3, 2026
0% โอกาส
ใหม่
ใหม่
Nov 3, 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ตลาดเปิดเมื่อ: Jul 1, 2026, 6:33 PM ET
ปริมาณการซื้อขาย
$2,851วันสิ้นสุด
Nov 3, 2026ตลาดเปิดเมื่อ
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ปริมาณการซื้อขาย
$2,851วันสิ้นสุด
Nov 3, 2026ตลาดเปิดเมื่อ
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย